New drug IBI3014 enters first human tests for Hard-to-Treat cancers
NCT ID NCT06974812
First seen Jan 30, 2026 · Last updated Jun 19, 2026 · Updated 20 times
Summary
This early-phase trial is testing an experimental drug called IBI3014 in 250 adults with advanced solid tumors that cannot be surgically removed. The study aims to find the safest dose and check whether the drug can shrink tumors. Participants receive IBI3014 by IV every three weeks at different dose levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fujian cancer hospital
RECRUITINGFuzhou, Fujian, 350014, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hunan Cancer Hospital
RECRUITINGChangsha, Hunan, 410000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Shanghai Pulmonary Hospital
RECRUITINGShanghai, Shanghai Municipality, 200433, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IBI3014 (an experimental drug given by IV infusion every 3 weeks)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors that cannot be removed by surgery.
What could go wrong
This is a very early, first-in-human study, so the drug may not shrink tumors or may cause unexpected side effects. Success in this small trial does not guarantee broader benefit.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.